Mylan Pharmaceuticals Inc. recalls Maxzide-25 (Triamterene and hydrochlorothiazide) tablets, USP, 37.5 mg/ 25 mg, 100-count bottle, Rx only, Mylan Pharmac
Recalled June 20, 2018 · FDA recall D-0877-2018 · Mylan Pharmaceuticals
Hazard
Superpotent Drug: Composite assay results obtained during routine stability testing were slightly above specification. · FDA Class III
Units
1,620 bottles
Sold at
Product was distributed throughout the United States
Description
Superpotent Drug: Composite assay results obtained during routine stability testing were slightly above specification.
Product
Maxzide-25 (Triamterene and hydrochlorothiazide) tablets, USP, 37.5 mg/ 25 mg, 100-count bottle, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, NDC 0378-0464-01
Manufacturer(s)
Mylan Pharmaceuticals Inc.
Source: U.S. Food and Drug Administration. Official recall notice on fda.gov →